文献速递生殖医学

无创胚胎植入前非整倍体检测DNA扩增失败率高且与滋养层活检结果一致性差

Noninvasive preimplantation genetic testing for aneuploidy exhibits high rates of deoxyribonucleic acid amplification failure and poor correlation with results obtained using trophectoderm biopsy.
PubMed 文献 · Fertil Steril · 2021-03-19

这项前瞻性队列研究分析了166枚囊胚及其培养液,评估商用无创胚胎植入前非整倍体检测(niPGT-A)的表现。结果显示niPGT-A的DNA扩增失败率为37.3%(62/166),而滋养层活检无失败;在104枚同时有niPGT-A和活检结果的胚胎中,全染色体不一致率为40.4%(42例)。结论认为当前形式的niPGT-A临床适用性有限。

要点

  • niPGT-A的DNA扩增失败率为37.3%(62/166),滋养层活检无扩增失败。
  • 培养液暴露时间短且活检无全染色体非整倍体的胚胎,niPGT-A扩增失败率更高。
  • niPGT-A与滋养层活检的全染色体不一致率为40.4%(42/104)。

核心结论

  • niPGT-A样本的DNA扩增失败率高,当前形式的niPGT-A几乎无法临床适用。

研究设计与样本

  • 前瞻性队列研究,纳入2019年7月至2020年5月间接受体外受精的夫妇的166枚囊胚及其周围培养液。

主要发现

  • niPGT-A的DNA扩增失败率为37.3%(62/166),而滋养层活检无胚胎出现DNA扩增失败。
  • 培养液暴露时间较短且滋养层活检无全染色体非整倍体证据的胚胎,niPGT-A扩增失败率高。
  • 在104枚同时有niPGT-A和滋养层活检结果的胚胎中,全染色体不一致率为40.4%(42例)。
  • 3枚经niPGT-A判定为非整倍体的胚胎最终成功分娩。

临床怎么用

  • 当前niPGT-A的DNA扩增失败率高且与滋养层活检结果一致性差,临床决策应谨慎依赖niPGT-A结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To validate a commercially available noninvasive preimplantation genetic testing for aneuploidy (niPGT-A) assay by investigating the following: prevalence of deoxyribonucleic acid (DNA) amplification failure with niPGT-A; factors affecting amplification failure with niPGT-A; and frequency of discordant results between niPGT-A and traditional preimplantation genetic testing for aneuploidy. DESIGN: Prospective cohort study SETTING: Academic-affiliated private practice PATIENT(S): One hundred sixty-six blastocysts and their surrounding culture media from couples undergoing in vitro fertilization between July 2019 and May 2020 were analyzed. INTERVENTION(S): Blastocyst-stage spent culture media samples underwent niPGT-A using a commercially available kit that used whole-genome amplification with a modified multiple annealing and looping-based amplification cycle protocol followed by next-generation sequencing. Preimplantation genetic testing for aneuploidy of trophectoderm (TE) biopsies was performed using targeted next-generation sequencing. MAIN OUTCOME MEASURE(S): The primary outcome was failure to achieve an interpretable result with niPGT-A. Factors affecting DNA amplification were also assessed. Discrepancies between niPGT-A and TE biopsy results were analyzed, and clinical outcomes were evaluated. RESULT(S): Deoxyribonucleic acid amplification failures with niPGT-A were observed in 37.3% (62/166) of the samples. With TE biopsy, no embryos exhibited DNA amplification failure. Embryos with a shorter duration of exposure to the culture media and no evidence of whole-chromosome aneuploidy on the TE biopsy displayed high rates of DNA amplification failure with niPGT-A. Of 104 embryos with both niPGT-A and TE biopsy results available, whole-chromosome discordance was noted in 42 cases (40.4%). Three embryos classified as aneuploid based on the niPGT-A result progressed to successful delivery. CONCLUSION(S): The rates of DNA amplification failure were high among the niPGT-A samples, virtually precluding the clinical applicability of niPGT-A in its current form.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Hanson BM, Tao X, Hong KH, et al. Noninvasive preimplantation genetic testing for aneuploidy exhibits high rates of deoxyribonucleic acid amplification failure and poor correlation with results obtained using trophectoderm biopsy. Fertil Steril. 2021. PMID: 33745720. doi:10.1016/j.fertnstert.2021.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。